Close this search box.

Acerta: Biggest biotech deal ever in the Netherlands

Pharmaceutical companies regularly come shopping in the Netherlands with a large bag of money. These pharmaceutical companies often buy the rights to a promising drug, and that’s always a bit of a gamble. An experimental drug is quickly promising, but the promise is not always fulfilled.

In 2015 the British-Swedish pharmaceutical company AstraZeneca did a large purchase in Oss. Biotech company Acerta Pharma was quietly working on a new drug against leukemia which was absolutely promising. AstraZeneca paid $2.5 billion for a 55% majority stake in Acerta, an unprecedented amount for a company with zero sales. It has turned out to be an excellent gamble. The experimental drug from Acerta has been approved without any problems and last year under the brand name Calquence had a turnover of $1.2 billion. This means that the drug has achieved the ‘blockbuster status’ that pharmaceutical companies are so eager to accomplish. Moreover, the growth is still strong. In the first six months of this year, AstraZeneca sold to Calquence for $0.9 billion. 

Read the full article here

Pivot Park Captains' Dinner

10 years ago, Pivot Park opened its doors to the world. Thanks to your commitment, support and confidence, we have been able to grow it into the successful and innovative biopharmaceutical campus it is today.

Now it’s time to celebrate!

We are therefore delighted to invite you – along with all your fellow CEOs at Pivot Park – to a special night out featuring inspiring art, a wonderful dinner and lots of opportunities to network and exchange ideas.

Erwin Wurm | Am I a House?

For the first time, the artist shows a cross-section of his work, from Narrow Furniture to One Minute Sculptures, within the walls of a historic building. Villa Constance, a former home that today houses Museum Jan Cunen, is not only a location but also part of the conversation. Because what exactly is a house?


The development of medicines in Oss began one hundred years ago. It was then that the foundations were laid for what would become a flourishing pharmaceutical sector in the Netherlands, leading to groundbreaking discoveries such as insulin and the anti-conception pill.

Today, the entire chain is still represented in Oss, from early-stage research to the commercial scale production of medicines. Working in Oss, we focus on the health of people all over the world. Employees at dozens of companies large and small put their heart and soul into new medicines, products and services that will improve lives worldwide. Together, our strength lies in our combination of broad knowledge about the development of medicines and a thorough understanding of the requirements of high-quality production.

This shared past and common values stimulate strong bonds among everyone who works in pharmaceuticals in Oss. We build on qualities, expertise and networks that go back decades. And with a wide variety of pharmaceutical companies, suppliers and scientific institutions all located nearby, we offer an attractive business climate and an excellent basis for international collaboration.

We are proud to work together to create a better and healthier future for all, a collaboration that in turn fuels growing employment: today, most pharmaceutical jobs in the Netherlands are in Oss. Here we connect talent and companies and stimulate entrepreneurship, while our expert employees are our most important asset. Their drive ensures that Oss has an influence on health all over the world.

Pharma in Oss offers endless opportunities to startups and talent in a city and region that is a joy to live and work in. We are committed to collaboration and sustainable and successful entrepreneurship. Oss’s pharmaceutical companies are intrinsically competitive while also being committed to quality and safety. This, plus their focus on new health solutions and contemporary technology, makes us a leader in our pursuit of a better life for people worldwide.